Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Abbas Jawadwala
Institution:
University at Buffalo, State University of New York
Observed institution:
University at Buffalo, State University of New York
ORCID:
0009-0009-8700-7005
Observed ORCID:
0009-0009-8700-7005
OpenAlex ID:
A5093808874
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
·
Cancer Research
·
2
Figure S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S4 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S6 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Data from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S5 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S2 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S7 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S3 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S1 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S4 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Figure S5 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
Table S1 from MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
2026
·
Surendra Gulla
, Tej Sharma
, et al.
The Role of KMT2D Knockdown in Advanced Prostate Cancer (Abstract ID: 232365)
2026
·
Afraz Yousuf
, Abbas Jawadwala
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
Abstract 5291: EZH2-AR non-canonical axis activation in TKI-resistant RCC: Differential effects of lenvatinib and cabozantinib
2026
·
Christian Migliarese
, Abbas Jawadwala
, et al.
·
Cancer Research
Abstract 3146: Targeting KMT2D enhances sensitivity to AKT inhibition in treatment resistant prostate cancer
2026
·
Abbas Jawadwala
, Remi M. Adelaiye-Ogala
, et al.
·
Cancer Research
Abstract 4764: Exploring the anti-proliferative impact of PBX1 perturbation in enzalutamide-resistant CRPC
2026
·
Ephraim J. Gardner
, Surendra Gulla
, et al.
·
Cancer Research
Abstract 5461: Molecular genetic profiling of a de novo neuroendocrine prostate cancer in a patient-derived xenograft (PDX) and organoid model from an African ancestry patient.
2026
·
Tej Sharma
, Surendra Gulla
, et al.
·
Cancer Research
Abstract 4742: Investigating the crosstalk between metabolic reprogramming and epigenetic modifications in bone metastatic prostate cancer
2026
·
Madison Aust
, Abbas Jawadwala
, et al.
·
Cancer Research
Abstract 6823: Dynamics of KMT2D modulation of the PI3K-Akt pathway and the impact on metastasis in prostate cancer
2025
·
Abbas Jawadwala
, Surrendra Gulla
, et al.
·
Cancer Research
Dietary interventions selectively target dysregulated metabolism and reveal metabolic vulnerabilities in preclinical models of advanced renal cell carcinoma.
2024
·
Sabrina Orsi
, Musea Chang
, et al.
·
Journal of Clinical Oncology
PDF
Abstract 1786: Metabolic rewiring induced by protein or calorie restriction provides unique therapeutic vulnerabilities in translocation and select clear cell renal cell carcinomas
2024
·
Sabrina A. Orsi
, Christopher Rupert
, et al.
·
Cancer Research
Abstract 7584: The solute transported xCT (SLC7A11) modulates lysosome biogenesis and microRNA trafficking in drug resistant renal cell carcinoma
2024
·
Abbas Jawadwala
, Christopher Rupert
, et al.
·
Cancer Research
Show more works
View as search
Works count:
27
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type